State-of-the-art for CAR T-cell therapy for chronic lymphocytic leukemia in 2019

Like solid tumors, cell and gene therapies for chronic, rather than acute, hematological conditions will present a significant jump in eligible patient population numbers and total costs to healthcare systems.